| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 6+ Months |
| 被験者数 | 23 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64, 65+ |
| 体型 | 肥満, 肥満 |
この研究の注釈：
10g of betaine twice daily over the course of one year in persons with nonalcoholic fatty liver appeared to significantly reduce ALT (), AST (), and ALP () liver enzyme values relative to baseline (no placebo control) with five subjects finding normalization of liver fat.
10g of betaine twice daily over the course of one year in persons with nonalcoholic fatty liver appeared to significantly reduce ALT (), AST (), and ALP () liver enzyme values relative to baseline (no placebo control) with five subjects finding normalization of liver fat.
In an intent to treat analysis, over 90% of subjects reported reductions in liver fat or inflammation in general; 36.4% of subjects who reported benefit to fibrosis scores (11 out of 23) had more than two stages of improvement, and only one subject had a worsening of fibrosis.
Betaine For Nonalcoholic Fatty Liver Disease: Results Of A Randomized Placebo-controlled Trial
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ Months |
| 被験者数 | 34 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64, 65+ |
| 体型 | 肥満 |
この研究の注釈：
Supplementation of 10g betaine twice daily for one year in persons with nonalcoholic fatty liver disease was able to increase methionine and SAMe levels, but did not reduce S-adenosylhomocysteine levels. Alongside this, there were failures to reduce liver enzymes or fibrotic scores, although liver fat (steatosis) was reduced with betaine and the progression of the disease state was lower in betaine relative to placebo.
Supplementation of 10g betaine twice daily for one year in persons with nonalcoholic fatty liver disease was able to increase methionine and SAMe levels, but did not reduce S-adenosylhomocysteine levels. Alongside this, there were failures to reduce liver enzymes or fibrotic scores, although liver fat (steatosis) was reduced with betaine and the progression of the disease state was lower in betaine relative to placebo.
General symptoms and well being was not different between groups.
Betaine, A Promising New Agent For Patients With Nonalcoholic Steatohepatitis: Results Of A Pilot Study
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 6+ Months |
| 被験者数 | 7 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満 |
この研究の注釈：
Supplementation of betaine at 500mg twice daily over the course of one year was able to fully normalize liver enzymes in three out of seven patients and reduce them by more than 50% in three others, with one nonresponder and the dropouts (before the year the trial lasted) also noting a 38-39% reduction.